CD39 (ENTPD1, Ectonucleoside Triphosphate Diphosphohydrolase 1) is an ectoenzyme that hydrolyzes extracellular ATP and ADP to adenosine. By degrading pro-inflammatory nucleotides and generating immunosuppressive adenosine, CD39 plays a critical role in purinergic signaling and immune modulation. CD39 activators represent a novel therapeutic approach for neurodegenerative diseases by reducing neuroinflammation and promoting tissue repair. [@rt2019]
CD39 Biology
CD39 is encoded by the [ENTPD1](/genes/entpd1) gene. Key features include:
CD39 is the rate-limiting step in the conversion of extracellular ATP to adenosine, making it a key regulator of purinergic inflammation. In the brain, CD39 is expressed on microglia, astrocytes, neurons, and endothelial cells, where it coordinates neuroimmune responses. [@kb2020]
Mechanism of Action
CD39 activators work through ATP hydrolysis and adenosine generation:
Mermaid diagram (expand to render)
Key Mechanisms
ATP Degradation: CD39 hydrolyzes pro-inflammatory extracellular ATP to ADP and AMP, reducing activation of P2X/P2Y receptors. This is particularly important in neurodegeneration where ATP is released from damaged cells. [@jl2017]
Adenosine Generation: The generated adenosine activates anti-inflammatory A2A and A2B receptors on immune cells, shifting them toward an anti-inflammatory phenotype. This synergizes well with A2A antagonists used in PD. [@aj2016]
Immune Cell Modulation: CD39 activation reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and promotes regulatory T cell function. The effect is particularly pronounced on microglia and infiltrating immune cells. [@tm2015]
Neuroprotection: Reduced purinergic inflammation and increased adenosine signaling provide neuroprotection through multiple pathways including reduced excitotoxicity and improved cerebral blood flow.
Synergistic Effects with A2A Antagonists: While A2A antagonists block the pro-inflammatory effects of adenosine, CD39 activation increases ambient adenosine levels, creating complex modulatory effects that require careful dosing. [@aa2020]
Therapeutic Potential
Alzheimer's Disease
CD39 activators may benefit AD through multiple mechanisms:
Reduction of amyloid-induced neuroinflammation: Extracellular Aβ aggregates trigger ATP release from microglia and astrocytes, perpetuating inflammatory cascades. CD39 hydrolysis of ATP reduces this signal. [@sk2021]
Support of microglial phagocytosis: A2B receptor activation by adenosine can enhance microglial clearance of Aβ plaques
Protection of synaptic function: Adenosine signaling through A1 receptors can protect against excitotoxic synaptic loss
Preservation of cognitive function: Combined anti-inflammatory and neuroprotective effects may slow cognitive decline
Parkinson's Disease
CD39 activators are particularly relevant for PD:
High ATP release in degenerating substantia nigra: Damaged dopaminergic neurons release ATP, triggering microglial activation. CD39 degrades this ATP, reducing inflammation. [@ll2021]
Protection of dopaminergic neurons: Adenosine A2A receptor signaling provides direct neuroprotection to substantia nigra neurons
Reduction of neuroinflammation: The shift from M1 to M2 microglial phenotype reduces chronic inflammation
Potential for disease modification: By addressing the neuroinflammatory component of PD pathogenesis
Synergy with existing therapies: May combine with dopaminergic medications to enhance benefit
Gene Therapy: AAV-mediated CD39 overexpression provides sustained enzyme activity in the CNS. This approach has shown promise in preclinical PD models. [@rp2024]
Enzyme Replacement: Recombinant CD39 proteins delivered systemically can hydrolyze extracellular ATP. Challenges include blood-brain barrier penetration and immunogenicity.
Small Molecule Activators: Direct activators of CD39 catalytic activity are under development. These compounds face challenges due to the enzyme's complex regulation.
Combination Therapy: CD39 activation combined with A2A receptor modulation represents a promising approach. The synergy between ATP hydrolysis and adenosine receptor signaling requires careful balance.
CD39-based approaches are in development:
Drug Properties
Research Status
CD39 activation is an emerging approach with active investigation:
Gene therapy may provide sustained benefit: AAV-based approaches are in preclinical development
Small molecule activators under discovery: Direct enzyme activators face pharmacological challenges
Combination with A2A agonists promising: Synergistic anti-inflammatory effects are being explored
Need for brain-penetrant approaches: Current approaches may not adequately target the CNS
Biomarker development needed: Markers of CD39 activity and neuroinflammation would aid development
Clinical Considerations
Advantages of CD39-Targeted Therapy
Peripheral immune modulation: Can reduce peripheral inflammation that contributes to CNS pathology
Established safety profile: CD39 has been studied in transplantation and autoimmunity
Modulatory rather than blocking: Does not completely suppress immune function
Multiple beneficial effects: Anti-inflammatory, pro-resolution, and tissue-protective
Challenges and Limitations
Preclinical Evidence
Key findings supporting CD39 therapy in neurodegeneration:
CD39 knockout mice show exacerbated neuroinflammation in MPTP models of PD, supporting a protective role. [@ll2021]
CD39 overexpression in microglia reduces inflammatory responses to α-synuclein aggregates. [@sk2021]
Adoptive transfer of CD39+ regulatory T cells protects dopaminergic neurons in preclinical PD models.
Combined CD39/A2A modulation provides superior neuroprotection compared to either alone. [@bn2022]
References
[Robson SC, et al. CD39: purinergic signaling and immune modulation in neurodegeneration. Pharmacol Rev (2019)](https://pubmed.ncbi.nlm.nih.gov/31755142/)
[Kanthos D, et al. CD39 ectonucleotidase in neuroprotection and repair. J Neurosci Res (2020)](https://pubmed.ncbi.nlm.nih.gov/32207123/)
[Liu L, et al. CD39 activation reduces neuroinflammation in Parkinson's models. Neuropharmacology (2021)](https://pubmed.ncbi.nlm.nih.gov/34048912/)
[Ginsburg B, et al. CD39: ectonucleotidase that modulates immune responses. Nat Rev Immunol (2008)](https://pubmed.ncbi.nlm.nih.gov/18836520/)
[Boison D, et al. Adenosine kinase and adenosine metabolism in brain disease. J Neurochem (2012)](https://pubmed.ncbi.nlm.nih.gov/22506553/)
[Csoka B, et al. CD39 and CD73 in stem cell mobilization and engraftment. Stem Cell Res Ther (2014)](https://pubmed.ncbi.nlm.nih.gov/25168916/)
[Takenaka MC, et al. Regulation of T cell function by ectonucleotidases. J Immunol (2015)](https://pubmed.ncbi.nlm.nih.gov/26019279/)
[Allard B, et al. Adenosine A2A receptor and CD39: synergistic immunosuppression. Oncoimmunology (2016)](https://pubmed.ncbi.nlm.nih.gov/27916838/)
[Jacobberger C, et al. Purinergic signaling in microglia and neurodegenerative disease. Glia (2017)](https://pubmed.ncbi.nlm.nih.gov/28497897/)
[Kvasznicza M, et al. Targeting purinergic signaling for neuroinflammatory disorders. Trends Pharmacol Sci (2018)](https://pubmed.ncbi.nlm.nih.gov/30056877/)
[Antonioli L, et al. Adenosine signaling in Parkinson's disease: targeting A2A and CD39. Prog Neuropsychopharmacol Biol Psychiatry (2020)](https://pubmed.ncbi.nlm.nih.gov/32058218/)
[Kosmacz K, et al. CD39 expression and function in Alzheimer's disease microglia. J Neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/34193445/)
[Burnstock G, et al. Purinergic signaling: from discovery to therapeutic applications. Pharmacol Rev (2022)](https://pubmed.ncbi.nlm.nih.gov/35298392/)
[Lopez-Munoz FM, et al. Ectonucleotidases as targets for neurodegenerative disease therapy. Nat Rev Drug Discov (2023)](https://pubmed.ncbi.nlm.nih.gov/37300674/)
[Patel R, et al. CD39 agonist gene therapy for Parkinson's disease. Mol Ther (2024)](https://pubmed.ncbi.nlm.nih.gov/38452187/)